{"name":"Laida Cuevas Palomares","slug":"laida-cuevas-palomares","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"RiTUXimab Injection [Truxima]","genericName":"RiTUXimab Injection [Truxima]","slug":"rituximab-injection-truxima","indication":"Non-Hodgkin's lymphoma (B-cell)","status":"marketed"}]}],"pipeline":[{"name":"RiTUXimab Injection [Truxima]","genericName":"RiTUXimab Injection [Truxima]","slug":"rituximab-injection-truxima","phase":"marketed","mechanism":"Rituximab is a chimeric monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis.","indications":["Non-Hodgkin's lymphoma (B-cell)","Chronic lymphocytic leukemia (CLL)","Rheumatoid arthritis","Granulomatosis with polyangiitis (GPA)","Microscopic polyangiitis (MPA)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}